Roche Experimenting With New Pricing Models In Oncology
Executive Summary
Cancer drug prices are unsustainable and creative approaches are needed, Roche’s O’Day says. The firm’s moves into emerging markets are a lab for new methods, he said, though the real test will come as the more expensive drugs are used in combination.
You may also be interested in...
Pfizer’s Bourla Defends Cancer Drug Pricing
“We should not discourage innovation right now,” Pfizer’s Group President of Vaccines, Oncology and Consumer Healthcare Albert Bourla said during a media briefing at the company headquarters.
Cancer Drug Pricing By Indication Worth Pursuing, Lilly Exec Suggests
Lilly has been considering ways to gather the kind of data that would enable it to price oncology drugs by tumor type, VP Oncology Newton Crenshaw says.
China, Emerging Markets In Focus For Genentech On Broad Avastin Access In Cervical Cancer
U.S. FDA approval is fifth indication for Roche/Genentech’s Avastin. The number of cases in the U.S. is low and set to decline with better prevention, but disease is still considered a major global health problem.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: